# Lupkynis (voclosporin) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/voclosporin

> The FDA approved Lupkynis (voclosporin), sponsored by Aurinia Pharmaceuticals Inc. (AUPH), on January 22, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Lupkynis (voclosporin) |
| Codes |  |
| Sponsor | Aurinia Pharmaceuticals Inc. (AUPH) https://sec-api.dev/companies/auph/catalysts |
| Indications | Adolescent Lupus Nephritis |
| Modality |  |
| FDA designations | priority review |

## Timeline

### January 22, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213716 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210122, review_priority PRIORITY; sponsor_name AURINIA; product LUPKYNIS (VOCLOSPORIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213716%22

### April 29, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213716 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20240429, review_priority STANDARD; sponsor_name AURINIA; product LUPKYNIS (VOCLOSPORIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213716%22

### July 3, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Adolescent Lupus Nephritis; Pediatric Lupus Nephritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05288855 (Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Aurinia Pharmaceuticals Inc.." https://clinicaltrials.gov/study/NCT05288855

### July 4, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Adolescent Lupus Nephritis; Pediatric Lupus Nephritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05962788 (Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-04 (ACTUAL); Lead Sponsor Aurinia Pharmaceuticals Inc.." https://clinicaltrials.gov/study/NCT05962788

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/voclosporin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lupkynis (voclosporin) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/voclosporin

```bibtex
@misc{secapidev_pdufa_voclosporin_20261116,
  title        = {Lupkynis (voclosporin) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/voclosporin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_voclosporin_20261116","title":"Lupkynis (voclosporin) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/voclosporin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
